Chester County News and Community Website
Headquartered in Berwyn, PA, Annovis Bio, Inc. (NYSE: ANVS) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS).
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has made strides in the fight against neurodegenerative diseases with the filing of three new patents. These cover novel combination therapies involving their …
Annovis Bio Files Patents for Innovative Therapies in Neurodegenerative Disease Treatment Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has announced its financial results for the second quarter ending June 30, 2024, along with significant business updates. The company highlighted positive …
Annovis Bio Reports Q2 2024 Financial Results and Business Progress Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) announced new preclinical data showing the positive combined effects of its lead compound, buntanetap, with the GLP-1 agonist dulaglutide (Trulicity®) in an …
Annovis Bio Shows Synergistic Effect of Buntanetap and Dulaglutide in Alzheimer’s Treatment Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has made a significant leap in the field of neurodegenerative disease treatment with the issuance of a U.S. patent for its lead …
Annovis Bio Secures Patent for Landmark TBI Treatment Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has received approval from the U.S. Food and Drug Administration (FDA) to transition to a new solid form of buntanetap in future …
Annovis Bio Gains FDA Approval for New Form of Neurodegenerative Drug Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has significantly bolstered its executive team by welcoming four industry professionals to its ranks. The move highlights Annovis’s efforts to innovative leadership …
Annovis Bio Boosts Executive Team with Four Industry Veterans Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) recently disclosed the encouraging results of its Phase III clinical trial related to Parkinson’s disease treatment. The experimental drug, buntanetap, has shown …
Annovis Bio’s Breakthrough in Parkinson’s Treatment: New Drug Buntanetap Shows Promise Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has filed a provisional patent covering the manufacturing process of novel solid forms of buntanetap. This move aims to strengthen the company’s …
Annovis Bio Files Provisional Patent for New Buntanetap Manufacturing Process Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has filed a new composition of matter patent with the U.S. Patent and Trademark Office. This patent covers novel crystalline forms of …
Annovis Bio Files Patent for New Crystal Form of Buntanetap Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) will host an investor webcast on July 2, 2024, at 4:30 PM ET to discuss recent progress and future plans for its …
Annovis Bio to Host Investor Webcast on Buntanetap Developments Read More